Danaher Corporation $DHR Shares Bought by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. increased its stake in Danaher Corporation (NYSE:DHR) by 24.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 14,117 shares of the conglomerate’s stock after acquiring an additional 2,788 shares during the period. Mufg Securities Americas Inc.’s holdings in Danaher were worth $2,789,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MGO One Seven LLC boosted its position in shares of Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock worth $5,145,000 after purchasing an additional 20,813 shares during the last quarter. Chicago Capital LLC raised its holdings in Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after buying an additional 1,391 shares during the period. UniSuper Management Pty Ltd lifted its position in Danaher by 1.6% in the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after acquiring an additional 2,667 shares in the last quarter. Nvwm LLC boosted its position in shares of Danaher by 20.4% during the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after buying an additional 1,204 shares during the period. Finally, ASR Vermogensbeheer N.V. boosted its position in Danaher by 1.9% during the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock worth $63,787,000 after acquiring an additional 6,136 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In related news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 3,298 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. This represents a 13.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 in the last ninety days. 11.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on DHR shares. TD Cowen upped their price objective on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Robert W. Baird set a $247.00 target price on Danaher in a research note on Wednesday, October 22nd. Redburn Partners set a $220.00 price objective on shares of Danaher in a report on Wednesday, October 8th. Cowen reiterated a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Finally, Evercore ISI lifted their price target on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Price Performance

Shares of DHR opened at $227.34 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The firm has a market cap of $160.58 billion, a PE ratio of 46.88, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The business’s 50 day moving average price is $208.58 and its two-hundred day moving average price is $201.97. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.71 earnings per share. On average, equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio is 26.39%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.